X4 Pharmaceuticals (NASDAQ:XFOR) Earns “Overweight” Rating from Cantor Fitzgerald

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They presently have a $3.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

X4 Pharmaceuticals Stock Up 0.6 %

Shares of XFOR stock opened at $0.27 on Wednesday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 12 month low of $0.24 and a 12 month high of $1.60. The stock has a market cap of $47.08 million, a P/E ratio of -3.01 and a beta of 0.39. The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.52.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million. On average, research analysts expect that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 over the last 90 days. 1.62% of the stock is owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its stake in X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth $30,000. XTX Topco Ltd lifted its stake in shares of X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after purchasing an additional 46,397 shares during the last quarter. SG Americas Securities LLC boosted its position in X4 Pharmaceuticals by 233.0% during the fourth quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock valued at $134,000 after purchasing an additional 128,148 shares in the last quarter. Finally, Atria Wealth Solutions Inc. bought a new stake in X4 Pharmaceuticals during the fourth quarter valued at about $44,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.